UCB Archive

2008

Date	Title
19-December	UCB Receives U.S. FDA Complete Response Letter for Neupro® (rotigotine transdermal system) in Restless Legs Syndrome and Advanced Parkinson’s Disease
31-October	Fesoterodine (fesoterodine fumarate) Approved in the U.S.
29-October	UCB’s Vimpat® (lacosamide) Approved by U.S. FDA as Adjunctive Therapy for Partial Onset Seizures in Adults
15-September	Keppra XR™ (levetiracetam extended-release tablets) Approved in the U.S.
29-July	UCB Receives Not-Approvable Letter from FDA for Lacosamide for Diabetic Neuropathic Pain
06-June	U.S. FDA Grants Pediatric Exclusivity for UCB’s Keppra® (levetiracetam)
20-May	Cimzia® (certolizumab pegol) Data Presented at the Digestive Disease Week (DDW) Meeting
22-April	Cimzia® (certolizumab pegol) Approved in the U.S. for the Treatment of Moderate to Severe Crohn’s Disease
20-March	UCB Advises U.S. Physicians to Down-Titrate Patients on Neupro® (rotigotine transdermal system) in View of Out-of-Stock Situation in the U.S.
19-February	FDA Approves XYZAL® (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
16-January	Keppra XR™ Extended-Release Tablets (levetiracetam) Filed with the FDA

Date	Title
13-December	Neupro® (rotigotine transdermalsystem) Filed with the FDA for the Treatment of Advanced-Stage Parkinson’s Disease
13-December	Neupro® (rotigotine transdermal system) Filed with the FDA for the Treatment of Restless Legs Syndrome
29-November	UCB Announces FDA Filing for Lacosamide in the Treatment of Diabetic Neuropathic Pain
29-November	UCB Announces FDA Filing for Lacosamide in the Treatment of Partial Onset Seizures in Adults with Epilepsy
04-October	UCB’s Keppra® (levetiracetam) Patent Litigation in the U.S. Settled
02-October	New Prescription Allergy Treatment Xyzal® (levocetirizine dihydrochloride) Now Available for Fall Allergy Season in the U.S.
16-July	UCB Announces the U.S. Launch of Neupro® (rotigotine transdermalsystem) for the Treatment of Early Stage Parkinson’s Disease
29-May	FDA Approves Xyzal® (levocetirizine dihydrochloride) Tablets for the Treatment of Seasonal and Year Round Allergies and Chronic Urticaria
23-March	UCB Provides Update on Cimzia™ (certolizumab pegol) for Crohn’s Disease and Rheumatoid Arthritis in the U.S.
20-March	Keppra® (levetiracetam) Approved for U.S. Epilepsy Patients with One of the Most Debilitating Seizure Types